Last update Sept. 7, 2025

比沙可啶

Compatible

Safe product and/or breastfeeding is the best option.

Intestinal stimulant laxative used in the treatment of constipation and for bowel evacuation prior to investigative procedures or surgery. Oral or rectal administration.

Its very low oral bioavailability due to minimal intestinal absorption results in very low plasma levels, which explains the absence of transfer to breast milk (undetectable levels). (Friedrich 2011)

Expert authors consider the use of this medication during breastfeeding to be acceptable. (Hale, LactMed, Gharehbaghi 2016)

On prevention or treating constipation, it is essential a balanced and rich-in-fiber diet along with a lot of fluids and physical exercise.

Alternatives

We do not have alternatives for 比沙可啶 since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

比沙可啶 is Bisacodyl in Chinese.

Is written in other languages:

Group

比沙可啶 belongs to this group or family:

Tradenames

Main tradenames from several countries containing 比沙可啶 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 5 - 16 %
Molecular weight 361 daltons
VD 2.6 l/Kg
Tmax 3 - 4 hours
7.3 hours
Theoretical Dose 0 mg/Kg/d
Relative Dose 0 %
Ped.Relat.Dose 0 %

References

  1. LactMed. Drugs and Lactation Database (LactMed). Internet. Bethesda (MD): National Library of Medicine (US); 2006-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK501922/ 2006 - Consulted on April 16, 2024 Full text (link to original source)
  2. Hale TW. Medications & Mothers' Milk. 1991- . Springer Publishing Company. Available from https://www.halesmeds.com Consulted on April 10, 2024 Full text (link to original source)
  3. Gharehbaghi K, Gharehbaghi DR, Wierrani F, Sliutz G. [Treatment of Chronic Functional Constipation during Pregnancy and Lactation]. Z Geburtshilfe Neonatol. 2016 Abstract
  4. Müller-Lissner S. Pharmacokinetic and pharmacodynamic considerations for the current chronic constipation treatments. Expert Opin Drug Metab Toxicol. 2013 Abstract
  5. AEMPS. Bisacodilo. Ficha técnica. 2012 Full text (in our servers)
  6. Friedrich C, Richter E, Trommeshauser D, de Kruif S, van Iersel T, Mandel K, Gessner U. Absence of excretion of the active moiety of bisacodyl and sodium picosulfate into human breast milk: an open-label, parallel-group, multiple-dose study in healthy lactating women. Drug Metab Pharmacokinet. 2011 Abstract Full text (link to original source) Full text (in our servers)

Total visits

3,540

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM